Is Pro Medicus (ASX:PME) overvalued?

TL;DR

Pro Medicus, a med tech business, has been seen as overvalued due to its high price-to-earnings (PE) ratio of 138, compared to the market average of 16-18. However, the future performance of the company, including contract wins and growth, is uncertain.

Transcript

foreign this week's video my name is Robert Galley and this week I thought I have a quick chat about a business that I've liked for a long time and uh yeah it's called Pro Medicus it's a what they call a med tech business so they make software that uh hospitals use in Radiology departments to help with the organization of their data their client fi... Read More

Key Insights

• 😷 Pro Medicus is a med tech business specializing in software for Radiology departments in hospitals.
• 🥳 The company has been considered overvalued due to its high PE ratio of 138, well above the market average of 16-18.
• 😉 Pro Medicus' valuation is based on backward-looking financials and does not account for future performance or contract wins.
• ❓ The recent 10-year contract with a Healthcare Group in Texas could potentially increase Pro Medicus' revenue and profitability.
• 😉 The uncertainty lies in the company's ability to sustain contract wins and continue its growth trajectory.
• 🎭 If Pro Medicus performs well and secures more profitable contracts, it may justify its current valuation.
• 😉 However, if the company faces client losses or a substantial decline in contract wins, its PE ratio and share price could decrease.

Questions & Answers

Q: What is Pro Medicus and what software do they provide?

Pro Medicus is a med tech business that offers software for Radiology departments in hospitals to organize their data and client files efficiently.

Q: Why is Pro Medicus considered overvalued?

Pro Medicus has a high price-to-earnings (PE) ratio of 138, which indicates that investors are paying 138 times the earnings per share to own a share of the company. This ratio is significantly higher than the market average of 16-18.

Q: How does the PE ratio reflect Pro Medicus' valuation?

The PE ratio is a backward-looking tool that takes into account the profit per share made in the past year divided by the current share price. It does not consider future performance, contract wins, or growth potential.

Q: How does Pro Medicus' recent contract announcement impact its valuation?

Pro Medicus recently secured a 10-year contract with a Healthcare Group in Texas, which could significantly boost its revenue and profitability. However, the long-term impact is uncertain as future contract wins and growth rates are unpredictable.

Summary & Key Takeaways

• Pro Medicus is a med tech company that provides software for Radiology departments in hospitals to manage their data and client files.

• The company has been deemed overvalued due to its high PE ratio of 138, well above the market average.

• Pro Medicus recently announced a 10-year contract with a Healthcare Group in Texas, which could potentially boost its revenue and profitability.